Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,880 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prospective study in bullous pemphigoid: association of high serum anti-BP180 IgG levels with increased mortality and reduced Karnofsky score.
Holtsche MM, Goletz S, van Beek N, Zillikens D, Benoit S, Harman K, Walton S, English J, Sticherling M, Chapman A, Levell NJ, Groves R, Williams HC, König IR, Schmidt E; members of the BLISTER Study Group. Holtsche MM, et al. Among authors: chapman a. Br J Dermatol. 2018 Oct;179(4):918-924. doi: 10.1111/bjd.16553. Epub 2018 Jul 5. Br J Dermatol. 2018. PMID: 29607480 Clinical Trial.
UK Dermatology Clinical Trials Network's STOP GAP trial (a multicentre trial of prednisolone versus ciclosporin for pyoderma gangrenosum): protocol for a randomised controlled trial.
Craig FF, Thomas KS, Mitchell EJ, Williams HC, Norrie J, Mason JM, Ormerod AD; UK Dermatology Clinical Trials Network’s STOP GAP Trial Team. Craig FF, et al. Trials. 2012 Apr 28;13:51. doi: 10.1186/1745-6215-13-51. Trials. 2012. PMID: 22540770 Free PMC article. Clinical Trial.
A randomized controlled trial to compare the safety and effectiveness of doxycycline (200 mg daily) with oral prednisolone (0.5 mg kg(-1) daily) for initial treatment of bullous pemphigoid: a protocol for the Bullous Pemphigoid Steroids and Tetracyclines (BLISTER) Trial.
Chalmers JR, Wojnarowska F, Kirtschig G, Nunn AJ, Bratton DJ, Mason J, Foster KA, Whitham D, Williams HC; BLISTER study group. Chalmers JR, et al. Br J Dermatol. 2015 Jul;173(1):227-34. doi: 10.1111/bjd.13729. Epub 2015 May 26. Br J Dermatol. 2015. PMID: 25683592 Clinical Trial.
Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial.
Williams HC, Wojnarowska F, Kirtschig G, Mason J, Godec TR, Schmidt E, Chalmers JR, Childs M, Walton S, Harman K, Chapman A, Whitham D, Nunn AJ; UK Dermatology Clinical Trials Network BLISTER Study Group. Williams HC, et al. Among authors: chapman a. Lancet. 2017 Apr 22;389(10079):1630-1638. doi: 10.1016/S0140-6736(17)30560-3. Epub 2017 Mar 6. Lancet. 2017. PMID: 28279484 Free PMC article. Clinical Trial.
A randomised controlled trial to compare the safety, effectiveness and cost-effectiveness of doxycycline (200 mg/day) with that of oral prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid: the Bullous Pemphigoid Steroids and Tetracyclines (BLISTER) trial.
Chalmers JR, Wojnarowska F, Kirtschig G, Mason J, Childs M, Whitham D, Harman K, Chapman A, Walton S, Schmidt E, Godec TR, Nunn AJ, Williams HC. Chalmers JR, et al. Among authors: chapman a. Health Technol Assess. 2017 Mar;21(10):1-90. doi: 10.3310/hta21100. Health Technol Assess. 2017. PMID: 28406394 Free PMC article. Clinical Trial.
Doxycycline compared with prednisolone therapy for patients with bullous pemphigoid: cost-effectiveness analysis of the BLISTER trial.
Mason JM, Chalmers JR, Godec T, Nunn AJ, Kirtschig G, Wojnarowska F, Childs M, Whitham D, Schmidt E, Harman K, Walton S, Chapman A, Williams HC; U.K. Dermatology Clinical Trials Network BLISTER Study Group. Mason JM, et al. Among authors: chapman a. Br J Dermatol. 2018 Feb;178(2):415-423. doi: 10.1111/bjd.16006. Epub 2018 Jan 15. Br J Dermatol. 2018. PMID: 28940316 Free PMC article. Clinical Trial.
Generating new evidence, improving clinical practice and developing research capacity: the benefits of recruiting to the U.K. Dermatology Clinical Trials Network's STOP GAP and BLISTER trials.
Batchelor JM, Chapman A, Craig FE, Harman KE, Kirtschig G, Martin-Clavijo A, Ormerod AD, Walton S, Williams HC. Batchelor JM, et al. Among authors: chapman a. Br J Dermatol. 2017 Nov;177(5):e228-e234. doi: 10.1111/bjd.15959. Epub 2017 Nov 10. Br J Dermatol. 2017. PMID: 29124728
Anakinra for palmoplantar pustulosis: results from a randomized, double-blind, multicentre, two-staged, adaptive placebo-controlled trial (APRICOT).
Cro S, Cornelius VR, Pink AE, Wilson R, Pushpa-Rajah A, Patel P, Abdul-Wahab A, August S, Azad J, Becher G, Chapman A, Dunnil G, Ferguson AD, Fogo A, Ghaffar SA, Ingram JR, Kavakleiva S, Ladoyanni E, Leman JA, Macbeth AE, Makrygeoegou A, Parslew R, Ryan AJ, Sharma A, Shipman AR, Sinclair C, Wachsmuth R, Woolf RT, Wright A, McAteer H, Barker JNWN, Burden AD, Griffiths CEM, Reynolds NJ, Warren RB, Lachmann HJ, Capon F, Smith CH; APRICOT Study Group. Cro S, et al. Among authors: chapman a. Br J Dermatol. 2021 Aug 19;186(2):245-56. doi: 10.1111/bjd.20653. Online ahead of print. Br J Dermatol. 2021. PMID: 34411292 Free PMC article.
1,880 results